| 000 | 01129 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250516090733.0 | ||
| 264 | 0 | _c20130114 | |
| 008 | 201301s 0 0 eng d | ||
| 022 | _a1744-7623 | ||
| 024 | 7 |
_a10.1517/14728214.2012.679263 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSchteingart, David E | |
| 245 | 0 | 0 |
_aDrugs in the medical treatment of Cushing's syndrome--an update on mifepristone and pasireotide. _h[electronic resource] |
| 260 |
_bExpert opinion on emerging drugs _cSep 2012 |
||
| 300 |
_a279-83 p. _bdigital |
||
| 500 | _aPublication Type: Editorial | ||
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 |
_aCushing Syndrome _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMifepristone _xadministration & dosage |
| 650 | 0 | 4 |
_aReceptors, Glucocorticoid _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptors, Somatostatin _xagonists |
| 650 | 0 | 4 |
_aSomatostatin _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 773 | 0 |
_tExpert opinion on emerging drugs _gvol. 17 _gno. 3 _gp. 279-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1517/14728214.2012.679263 _zAvailable from publisher's website |
| 999 |
_c21731836 _d21731836 |
||